Acino Pharma GmbH Sustainability Profile
Acino Pharma GmbH, a prominent player in the pharmaceutical industry, is headquartered in Germany and operates extensively across Europe, the Middle East, and Africa. Founded in 1836, Acino has established itself as a leader in the development and manufacturing of high-quality generic and specialty pharmaceuticals, focusing on areas such as pain management, cardiovascular health, and central nervous system disorders. The company is renowned for its innovative drug delivery systems and patient-centric solutions, which set its products apart in a competitive market. With a commitment to quality and sustainability, Acino has achieved significant milestones, including strategic partnerships and expansions that enhance its market position. As a trusted name in healthcare, Acino Pharma continues to make strides in improving patient outcomes through its diverse portfolio of effective medications.
DitchCarbon Score
How does Acino Pharma GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Acino Pharma GmbH's score of 3 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Acino Pharma GmbH, headquartered in Germany (DE), currently does not report specific carbon emissions data, as no figures are available. The company is a current subsidiary of Acino International AG, which may influence its climate-related performance metrics. Despite the absence of direct emissions data, Acino Pharma GmbH is part of a corporate family that may have broader climate commitments. However, there are no documented reduction targets or climate pledges available for Acino Pharma GmbH at this time. As a pharmaceutical company, Acino Pharma GmbH operates within an industry increasingly focused on sustainability and reducing carbon footprints. The lack of specific emissions data highlights a potential area for improvement in transparency and accountability regarding climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 5,047,200 |
| Scope 2 | 3,209,000 |
| Scope 3 | - |
How Carbon Intensive is Acino Pharma GmbH's Industry?
How Carbon Intensive is Acino Pharma GmbH's Location?
Acino Pharma GmbH's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Acino Pharma GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
